MedPath

Conatumumab

Generic Name
Conatumumab
Drug Type
Biotech
CAS Number
896731-82-1
Unique Ingredient Identifier
1P48L61KM0
Background

Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.

Clinical Trials
Related News

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Phase 1
Completed
Conditions
Relapsed Epithelial Ovarian Cancer
Relapsed Fallopian Tube Cancer
Relapsed Primary Peritoneal Cancer
Interventions
First Posted Date
2013-09-12
Last Posted Date
2016-01-14
Lead Sponsor
TetraLogic Pharmaceuticals
Target Recruit Count
27
Registration Number
NCT01940172
Locations
🇺🇸

TetraLogic research site, Fresno, California, United States

🇺🇸

TetraLogic Research Site, Nashville, Tennessee, United States

🇺🇸

TetraLogic Research Facility, Dallas, Texas, United States

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Phase 1
Completed
Conditions
Low Grade Lymphoma
Hodgkin's Lymphoma
Lymphoma
Mantle Cell Lymphoma
Non-Hodgkin's Lymphoma
Diffuse Large Cell Lymphoma
Interventions
Other: Vorinostat
Other: Bortezomib
First Posted Date
2008-11-14
Last Posted Date
2014-03-05
Lead Sponsor
Amgen
Target Recruit Count
33
Registration Number
NCT00791011

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Phase 1
Completed
Conditions
Colon Cancer
Rectal Cancer
Colorectal Cancer
Metastatic Colorectal Cancer
Oncology
Interventions
First Posted Date
2008-03-07
Last Posted Date
2014-02-06
Lead Sponsor
Amgen
Target Recruit Count
53
Registration Number
NCT00630786

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Phase 1
Completed
Conditions
Metastatic Pancreatic Cancer
Pancreatic Cancer
Adenocarcinoma of the Pancreas
Interventions
Other: Placebo
First Posted Date
2008-03-07
Last Posted Date
2024-10-17
Lead Sponsor
NantCell, Inc.
Target Recruit Count
138
Registration Number
NCT00630552
Locations
🇺🇸

Research Site, Yakima, Washington, United States

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Phase 1
Completed
Conditions
Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma
Sarcoma
Soft Tissue Sarcoma
Interventions
Other: Placebo
First Posted Date
2008-02-29
Last Posted Date
2015-05-25
Lead Sponsor
Amgen
Target Recruit Count
134
Registration Number
NCT00626704

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Metastatic Colorectal Cancer
Colon Cancer
Colorectal Cancer
Rectal Cancer
Interventions
Drug: Placebo
Drug: Modified FOLFOX6
First Posted Date
2008-02-28
Last Posted Date
2014-04-25
Lead Sponsor
Amgen
Target Recruit Count
202
Registration Number
NCT00625651
Locations
🇺🇸

Research Site, Vancouver, Washington, United States

A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Phase 1
Completed
Conditions
Non-Small Cell Lung Cancer
Interventions
Other: AMG 655 placebo
First Posted Date
2007-09-24
Last Posted Date
2016-01-14
Lead Sponsor
Amgen
Target Recruit Count
172
Registration Number
NCT00534027
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy